Pfizer’s plan to quadruple US prices for its COVID-19 vaccine next year is beyond Wall Street’s expectations and will spur its revenue for years despite weaker than anticipated demand for the new booster shot so far, analysts said. www.reuters.com/business/healthcare-pharmaceuticals/pfizer-covid-vaccine-price-hike-seen-giving-revenue-boost-years-2022-10-21/?
The drugmaker, which developed and sells the vaccine with Germany’s BioNTech (22UAy.DE), said on Thursday evening that it is targeting a range of $110 to $130 a dose for the vaccine once the US moves to a commercial market next year.
Analysts said the move could lead to price hikes by rivals.
The US is one of the biggest customers for the Pfizer/BioNTech COVID-19 shots.
Lalita Panicker is consulting editor, views, Hindustan Times, New Delhi